Form 8-K - Current report:
SEC Accession No. 0001193125-26-272890
Filing Date
2026-06-16
Accepted
2026-06-16 17:18:15
Documents
9
Period of Report
2026-06-16
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K cgem-20260616.htm   iXBRL 8-K 65546
  Complete submission text file 0001193125-26-272890.txt   171865

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20260616.xsd EX-101.SCH 24922
12 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20260616_htm.xml XML 4711
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

EIN.: 813879991 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39856 | Film No.: 261095784
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)